Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

RAAS inhibitors and cardiovascular protection in large scale trials.

von Lueder TG, Krum H.

Cardiovasc Drugs Ther. 2013 Apr;27(2):171-9. doi: 10.1007/s10557-012-6424-y. Review.

PMID:
23224653
2.

Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.

Alfie J, Aparicio LS, Waisman GD.

Rev Recent Clin Trials. 2011 May;6(2):134-46. Review.

PMID:
21241234
3.

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Werner C, Pöss J, Böhm M.

Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Review.

PMID:
20568830
4.

Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

Cagnoni F, Njwe CA, Zaninelli A, Ricci AR, Daffra D, D'Ospina A, Preti P, Destro M.

Vasc Health Risk Manag. 2010 Aug 9;6:549-59. Review.

5.

Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.

Rao MS.

J Assoc Physicians India. 2010 Feb;58:102-8. Review.

PMID:
20653151
6.

Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?

Bavishi C, Bangalore S, Messerli FH.

Prog Cardiovasc Dis. 2016 Nov - Dec;59(3):253-261. doi: 10.1016/j.pcad.2016.10.002. Epub 2016 Oct 21. Review.

PMID:
27777044
7.

Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.

Slomka T, Lennon ES, Akbar H, Gosmanova EO, Bhattacharya SK, Oliphant CS, Khouzam RN.

Am J Med Sci. 2016 Mar;351(3):309-16. doi: 10.1016/j.amjms.2015.12.021. Review.

PMID:
26992264
8.

The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.

Epstein BJ, Leonard PT, Shah NK.

Expert Rev Cardiovasc Ther. 2012 Jun;10(6):713-25. doi: 10.1586/erc.12.63. Review.

PMID:
22894628
9.
10.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
11.

Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system.

Cohn JN.

Adv Ther. 2007 Nov-Dec;24(6):1290-304. Review.

PMID:
18165212
12.

Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.

Farcas A, Leucuta D, Bucsa C, Mogosan C, Dumitrascu D.

Int J Clin Pharm. 2016 Dec;38(6):1390-1397. Epub 2016 Sep 27.

PMID:
27677980
13.
14.

It is time to reconsider the cardiovascular protection afforded by RAAS blockade -- overview of RAAS systems.

Tsukamoto O, Kitakaze M.

Cardiovasc Drugs Ther. 2013 Apr;27(2):133-8. doi: 10.1007/s10557-011-6361-1.

PMID:
22147138
15.

Hypertension: renin-angiotensin-aldosterone system alterations.

Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH.

Circ Res. 2015 Mar 13;116(6):960-75. doi: 10.1161/CIRCRESAHA.116.303587. Review.

16.

An update of the blockade of the renin angiotensin aldosterone system in clinical practice.

Márquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J.

Expert Opin Pharmacother. 2015;16(15):2283-92. doi: 10.1517/14656566.2015.1079623. Epub 2015 Sep 7. Review.

PMID:
26389772
17.

Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.

Lambers Heerspink HJ, Perkovic V, de Zeeuw D.

J Hypertens. 2009 Dec;27(12):2321-31. doi: 10.1097/HJH.0b013e3283310f92. Review.

PMID:
19727007
18.

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A.

Expert Opin Pharmacother. 2007 Apr;8(5):529-35. Review.

PMID:
17376010
19.

Novel RAAS agonists and antagonists: clinical applications and controversies.

Romero CA, Orias M, Weir MR.

Nat Rev Endocrinol. 2015 Apr;11(4):242-52. doi: 10.1038/nrendo.2015.6. Epub 2015 Feb 10. Review.

PMID:
25666495
20.

Reducing cardiorenal risk through combination therapy with a direct renin inhibitor.

Rastogi A, Rashid M, Wright RF.

J Clin Hypertens (Greenwich). 2011 Nov;13(11):848-55. doi: 10.1111/j.1751-7176.2011.00536.x. Epub 2011 Oct 28. Review.

Supplemental Content

Support Center